Fibromyalgia: Updated Diagnosis, Exercise, CBT and 2026 Medication Options
Evidence-based fibromyalgia guide: 2016 ACR pain criteria, fatigue and fibro fog, exercise and CBT, pregabalin/duloxetine/milnacipran and 2025 FDA-approved Tonmya.
Evidence-based fibromyalgia guide: 2016 ACR pain criteria, fatigue and fibro fog, exercise and CBT, pregabalin/duloxetine/milnacipran and 2025 FDA-approved Tonmya.
Evidence-based cholesterol diet with soluble fiber, plant sterols, unsaturated fats, Mediterranean eating, triglyceride advice, 2026 ACC/AHA PREVENT risk assessment and LDL targets.
Evidence-based Graves disease guide: TSH and free T4/T3, TRAb testing, methimazole/carbimazole, PTU precautions, radioiodine, surgery, thyroid eye disease and 2026 pregnancy guidance.
Evidence-based hypothyroidism guide: Hashimoto disease, TSH and free T4 interpretation, central and subclinical hypothyroidism, levothyroxine timing, monitoring and 2026 ATA pregnancy recommendations.
Compare OA versus RA joint symptoms, imaging, RF and anti-CCP tests, 2026 ACR osteoarthritis guidance, 2025 EULAR RA DMARD recommendations and medication safety.
Updated COPD guide: post-bronchodilator spirometry, GOLD 2026 A/B/E groups, LABA/LAMA/ICS decisions, eosinophils, dupilumab and mepolizumab, exacerbations and rehabilitation.
Evidence-based GINA 2026 asthma guide to symptoms, spirometry, triggers, ICS-formoterol relievers, MART, exacerbation action plans, childhood asthma, inhaler technique and biologics.
Evidence-based hypertension guide with 2025 AHA/ACC BP stages, PREVENT risk thresholds, DASH nutrition, sodium reduction, accurate home monitoring, medicines and emergency signs.
Updated type 1 diabetes education on autoimmune beta-cell loss, diagnosis, lifelong insulin, 2026 ADA continuous glucose monitoring and automated insulin delivery, hypoglycemia, ketones and DKA.
Comprehensive 2026 ADA type 2 diabetes guide: diagnosis, individualized A1C, metformin, GLP-1 and GIP/GLP-1 drugs, SGLT2 inhibitors for heart/kidney protection, insulin and monitoring.